Adverse drug reactions evaluation of antimicrobials in COVID-19 inpatients using Modified Trigger Tool and Naranjo Algorithm

Author:

Kusumawardani Larasati Arrum,Maria NisaORCID,Amarta Yoga

Abstract

Background: The use of antimicrobials in COVID-19 treatment might increase the risk of adverse drug reactions (ADR). Therefore, the adverse effect further identification was needed to understand the safety profile of using these medicines.    Objective: The research aims to evaluate the adverse effects of the use of COVID-19 antimicrobial agents, causality analysis, and factors related to this ADR.    Method: Cross-sectional study using random sampling was conducted to obtain the data. The study used samples from COVID-19 adult inpatients in a hospital located in Java from July-December 2020. Adverse events (AE) were detected by a modified trigger tool using medication and laboratory result module triggers with 21 total triggers. Causality analysis of ADR was conducted using Naranjo Scale.    Result: Of the 107 patients examined in this study, 92 patients had triggers. A total of 274 adverse events were found, where 265 adverse events were detected using the trigger tool, and 9 adverse events were detected without the trigger tool. The results of the ADR analysis using the Naranjo algorithm were obtained from as many as 126 ADRs in 60 patients with possible (94.4%) and probable (5.6%) scoring. The most common antimicrobials that cause ADR were azithromycin and oseltamivir. The most effective trigger in detecting ADR was the use of sedation with a positive predictive value of 0.67. The statistical analysis results showed no relationship between gender, age, comorbidities, severity, and body mass index on the incidence of ADR (p>0.05).    Conclusion: Adverse drug reactions were commonly found in the use of azithromycin and oseltamivir for COVID-19 patients, so it is necessary to consider the choice of this therapy. The trigger tool and Naranjo algorithm were adequate to help the ADR monitoring process.

Publisher

International Pharmaceutical Federation (FIP)

Subject

Pharmaceutical Science,Pharmacy,Education,Industrial and Manufacturing Engineering,Materials Science (miscellaneous),Business and International Management

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3